Lantheus Holdings, Inc. (LNTH)
NASDAQ: LNTH · IEX Real-Time Price · USD
112.71
-0.24 (-0.21%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Lantheus Holdings Revenue
Lantheus Holdings had revenue of $369.98M in the quarter ending March 31, 2024, with 23.00% growth. This brings the company's revenue in the last twelve months to $1.37B, up 32.98% year-over-year. In the year 2023, Lantheus Holdings had annual revenue of $1.30B with 38.65% growth.
Revenue (ttm)
$1.37B
Revenue Growth
+32.98%
P/S Ratio
5.79
Revenue / Employee
$1,637,434
Employees
834
Market Cap
7.81B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.30B | 361.37M | 38.65% |
Dec 31, 2022 | 935.06M | 509.85M | 119.91% |
Dec 31, 2021 | 425.21M | 85.80M | 25.28% |
Dec 31, 2020 | 339.41M | -7.93M | -2.28% |
Dec 31, 2019 | 347.34M | 3.96M | 1.15% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
The Ensign Group | 3.97B |
Chemed | 2.29B |
Ionis Pharmaceuticals | 776.62M |
Repligen | 607.45M |
Intra-Cellular Therapies | 513.93M |
Ascendis Pharma | 357.63M |
Roivant Sciences | 124.80M |
Revolution Medicines | 4.57M |
LNTH News
- 9 days ago - Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time - GlobeNewsWire
- 11 days ago - Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease - GlobeNewsWire
- 16 days ago - Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access - GlobeNewsWire
- 18 days ago - Lantheus Appoints Jamie Spaeth as Chief People Officer - GlobeNewsWire
- 4 weeks ago - Lantheus Acquires Global Rights to Life Molecular Imaging's Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers - GlobeNewsWire
- 5 weeks ago - Radiopharm Receives Strategic Investment for up to A$18 million - GlobeNewsWire
- 7 weeks ago - Lantheus' AI-Enabled aPROMISE Now Available on Siemens Healthineers' syngo.via platform - GlobeNewsWire
- 2 months ago - Lantheus to Present at the William Blair 44th Annual Growth Stock Conference - GlobeNewsWire